Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer

Published:2014-11 Issue:11 Volume:9 Page:1625-1633
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Blackhall Fiona,Kim Dong-Wan,Besse Benjamin,Nokihara Hiroshi,Han Ji-Youn,Wilner Keith D.,Reisman Arlene,Iyer Shrividya,Hirsh Vera,Shaw Alice T.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Assessing coughing and wheezing in lung cancer: a pilot study;Chernecky;Oncol Nurs Forum,2004

2. Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany;Iyer;Lung Cancer,2013

3. A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue;Molassiotis;Lung Cancer,2011

4. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment;Hopwood;Br J Cancer,1995

5. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews;Silvestri;BMJ,1998

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study;Frontiers in Pharmacology;2024-09-06

2. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis;BMC Cancer;2024-02-08

3. Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping;Value in Health;2023-08

4. Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis;Lung Cancer Management;2023-06

5. Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis;International Journal of Molecular Sciences;2023-05-17